A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2018
At a glance
- Drugs AZD 1390 (Primary)
- Indications Brain metastases; Glioblastoma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 23 Apr 2018 Planned End Date changed from 26 Mar 2021 to 5 Apr 2021.
- 23 Apr 2018 Planned primary completion date changed from 26 Mar 2021 to 5 Apr 2021.
- 23 Apr 2018 Status changed from not yet recruiting to recruiting.